Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Xuan Zou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0001-7345-9467; OpenAlex author ID A5101637193. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 4 papers · 2024: 4 papers · 2025: 1 paper

Papers 12

  1. Assessment of tertiary lymphoid structures via 18F-FDG PET/CT scan in patients with pancreatic adenocarcinoma. First author DOI 10.1007/s00262-025-04205-x↗
  2. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03648-y↗
  3. DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer. Co-author DOI 10.1007/s00262-024-03786-3↗
  4. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applic… Co-author DOI 10.1016/j.canlet.2024.216741↗
  5. Efficacy of Hyperthermic Intraperitoneal Chemotherapy Alone for Diffuse Peritoneal Carcinomatosis from Pancreatic Adenocarcinoma: A Single-Centre Retrospective… Co-author DOI 10.21203/rs.3.rs-4011964/v1↗
  6. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance. Co-author DOI 10.1136/jitc-2023-006698↗
  7. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12876-023-02748-w↗
  8. Characterization of Estrogen Receptors in Pancreatic Adenocarcinoma with Tertiary Lymphoid Structures. Co-author DOI 10.3390/cancers15030828↗
  9. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/curroncol30020126↗
  10. Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41389-022-00411-9↗
  11. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2022/7353572↗
  12. Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. Co-author DOI 10.1002/cam4.2145↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xuan Lin · 11 shared papers, 2022–2025 · strength 1.96
  2. Xianjun Yu · 11 shared papers, 2022–2025 · strength 1.96
  3. Yusheng Chen · 10 shared papers, 2022–2025 · strength 1.80
  4. Xu Wang · 9 shared papers, 2022–2025 · strength 1.56
  5. Zhengjie Dai · 9 shared papers, 2022–2024 · strength 1.53
  6. He Cheng · 8 shared papers, 2022–2025 · strength 1.39
  7. Yesiboli Tasiheng · 8 shared papers, 2022–2024 · strength 1.33
  8. Mingjian Ma · 7 shared papers, 2023–2025 · strength 1.31
  9. Chen Liu · 7 shared papers, 2022–2025 · strength 1.20
  10. Yu Yan · 4 shared papers, 2023–2025 · strength 0.76
  11. Chen Liu · 3 shared papers, 2023–2024 · strength 0.55
  12. Yunzhen Qian · 3 shared papers, 2022–2023 · strength 0.44
  13. Yitao Gong · 2 shared papers, 2022 · strength 0.27
  14. Guopei Luo · 2 shared papers, 2022 · strength 0.27
  15. He Cheng · 1 shared paper, 2024 · strength 0.20
  16. Yu Liu · 1 shared paper, 2024 · strength 0.20
  17. Chen Liu · 1 shared paper, 2024 · strength 0.20
  18. Yu Liu · 1 shared paper, 2023 · strength 0.18
  19. Yusheng Chen · 1 shared paper, 2023 · strength 0.16
  20. Cheng He · 1 shared paper, 2023 · strength 0.16
  21. Fei Ding · 1 shared paper, 2023 · strength 0.15
  22. Zipeng Lu · 1 shared paper, 2019 · strength 0.11
  23. Xin Min ZHOU · 1 shared paper, 2019 · strength 0.11
  24. Jishu Wei · 1 shared paper, 2019 · strength 0.11
  25. Yi Miao · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.